A randomized double-blind controlled trial to assess the efficacy and safety of curcumin versus placebo in active rheumatoid arthritis patients

Phase 4

Recruiting

• Conditions: Active rheumatoid arthritis patients; Rheumatoid arthritis

• Registration Number: TCTR20181115012
• Lead Sponsor: Rheumatic Disease Unit, Department of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-15
• Study Completion: 2018-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

RA (2010 ACR/EULAR criteria)
Age ≥ 18 years old
At least moderate disease activity (DAS 28 >3.2)
VAS ≥ 50
Stable dose DMARDs therapy at least 1 month prior to randomization
Inaccessible or denied add on therapy

Exclusion Criteria

Allergy to tumeric
Pregnant or breast feeding
Subjects with any current malignancy and on chemotherapy
On anticoagulant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
DAS-28 score 8 weeks Composite end point

Secondary Outcome Measures

Name	Time	Method
ACR 20 8 weeks Composite endpoint